Skip to main content
SpringerLink
Log in

Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Interaction between cigarette smoking and efficacy of oral antiplatelet drugs is not definitely elucidated. We evaluated the effects of cigarette smoking on platelet reactivity in patients receiving different oral P2Y12 antagonists after myocardial infarction (MI) and drug-eluting stent (DES) implantation. Two-hundred-five consecutive current smokers receiving DES implantation after ST-segment elevation MI were enrolled. All patients were aspirin-treated and were on chronic therapy with clopidogrel (N = 59), prasugrel (N = 71) or ticagrelor (N = 75); by protocol, all patients at baseline had no high on-treatment platelet reactivity by the VerifyNow P2Y12 assay. Platelet reactivity, expressed by P2Y12 reaction units (PRU), was measured in all patients at baseline (T0), after a 15-day period of smoking cessation (T1) and after further 15 days of smoking resumption (T2). In the overall population there was a modest, albeit significant, reduction of PRU values from T0 to T1 (from 173 ± 14 to 165 ± 17, P < 0.0001); resumption of cigarette smoking was associated with re-increase of platelet reactivity (from 165 ± 17 at T1 to 170 ± 17 at T2, P = 0.0002). These variations were consistent in the subgroups receiving clopidogrel, prasugrel or ticagrelor and were irrespective of the number of cigarettes smoked. In conclusion, cigarette smoking weakly influences antiplatelet effects of oral P2Y12 inhibition and this was irrespective of the type of antiplatelet agent; thus, interaction between cigarette smoking and efficacy of oral antiplatelet drugs is modest and unlikely translates into clinical effects (ClinicalTrials.gov Identifier: NCT02026713).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rea TD, Heckbert SR, Kaplan RC et al (2002) Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 137:494–500

    Article  PubMed  Google Scholar 

  2. Twardella D, Kupper-Nuybelen J, Rothenbacher D et al (2004) Short-term benefit of smoking cessation in patients with coronary heart disease: estimates based on self-reported smoking data and serum cotinine measurements. Eur Heart J 25:2101–2108

    Article  PubMed  Google Scholar 

  3. Barbash GI, White HD, Modan M et al (1995) Acute myocardial infarction in the young: the role of smoking. Eur Heart J 16:313–316

    CAS  PubMed  Google Scholar 

  4. Ferreiro JL, Bhatt D, Ueno M et al (2012) Differential effect of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the clopidogrel versus aspirin in patients at risk of ischemic events trial [abstract]. J Am Coll Cardiol 59:A62

    Article  Google Scholar 

  5. Salek FS (2010) Relationship between clopidogrel and cigarette smoking status in patients with acute coronary syndromes without ST-segment elevation myocardial infarction [abstract]. Pharmacotherapy 30:154e

    Google Scholar 

  6. Saraff KY, Steinhubl SR, Hsu AP, Topol EJ (2006) Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following PCI [abstract]. J Am Coll Cardiol 47(4):36B

    Google Scholar 

  7. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mehta SR, Tanguay JF, Eikelboom JW et al (2010) CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243

    Article  CAS  PubMed  Google Scholar 

  9. Berger JS, Bhatt DL, Steinhubl SR et al (2009) CHARISMA Investigators. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 120:2337–2344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zevin S, Benowitz NL (1999) Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 36:425–438

    Article  CAS  PubMed  Google Scholar 

  11. Kroon LA (2007) Drug interactions with smoking. Am J Health Syst Pharm 64:1917–1921

    Article  CAS  PubMed  Google Scholar 

  12. Bliden KP, Dichiara J, Lawal L et al (2008) The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 52:531–533

    Article  CAS  PubMed  Google Scholar 

  13. Gurbel PA, Bliden KP, Logan DK et al (2013) The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 62:505–512

    Article  CAS  PubMed  Google Scholar 

  14. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V (2006) Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28:315–322

    Article  CAS  PubMed  Google Scholar 

  15. Malinin A, Pokov A, Spergling M et al (2007) Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: the VERIfy thrombosis risk assessment (VERITAS) study. Thromb Res 119:277–284

    Article  CAS  PubMed  Google Scholar 

  16. Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty—platelet reactivity predicts outcome) study. J Am Coll Cardiol 52:1128–1133

    Article  CAS  PubMed  Google Scholar 

  17. Ueno M, Ferreiro JL, Desai B et al (2012) Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. J Am Coll Cardiol Intv 5:293–300

    Article  Google Scholar 

  18. Hochholzer W, Trenk D, Mega JL et al (2011) Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J 162(518–26):e5

    PubMed  Google Scholar 

  19. Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in st-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 61:1601–1606

    Article  CAS  PubMed  Google Scholar 

  20. Alexopoulos D, Galati A, Xanthopoulou I et al (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high onclopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60:193–199

    Article  CAS  PubMed  Google Scholar 

  21. Perl L, Zemer-Wassercug N, Rechavia E et al (2014) Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction. J Thromb Thrombolysis. doi:10.1007/s11239-014-1119-9

    Google Scholar 

  22. Brar SS, ten Berg J, Marcucci R et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58:1945–1954

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The present study was not supported by any grant or outside sources of funding or industry sponsorship.

Author information

Author notes

    Authors and Affiliations

    1. Campus Bio-Medico University of Rome, Rome, Italy

      Giuseppe Patti

    2. Department “Attilio Reale”, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy

      Marina Polacco, Ester Taurino, Carlo Gaudio & Cesare Greco

    Authors
    1. Giuseppe Patti
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Marina Polacco
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Ester Taurino
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Carlo Gaudio
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Cesare Greco
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Cesare Greco.

    Ethics declarations

    Conflict of interest

    No conflict of interest to disclose.

    Additional information

    Giuseppe Patti and Marina Polacco have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Patti, G., Polacco, M., Taurino, E. et al. Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study. J Thromb Thrombolysis 41, 648–653 (2016). https://doi.org/10.1007/s11239-016-1341-8

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11239-016-1341-8

    Keywords

    Search

    Navigation